Skip to Main Content
Contribute Try STAT+ Today

In a bid to expand access to a key AIDS drug, ViiV Healthcare and the Medicines Patent Pool reached an agreement that will allow generic manufacturers to provide the Tivicay treatment to four upper-middle-income countries by 50% to 70% off existing interim pricing.

The arrangement will make it possible for lower-cost versions to reach Azerbaijan, Belarus, Kazakhstan, and Malaysia after the countries balked at being excluded from a 2014 licensing agreement that covers dozens of lower and middle-income nations. Although classified by the World Bank as upper middle-income nations, all four governments argued that current pricing prevented many patients from being treated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.